6533b821fe1ef96bd127b77b

RESEARCH PRODUCT

The inorganic polymer, polyphosphate, blocks binding of SARS-CoV-2 spike protein to ACE2 receptor at physiological concentrations

Meik NeufurthEmad TolbaXiaohong WangShunfeng WangWerner E. G. MüllerHeinz C. SchröderIngo Lieberwirth

subject

Models Molecular0301 basic medicineAntiviral AgentsBiochemistryArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePolyphosphatesPolyphosphateHuman Umbilical Vein Endothelial Cellsotorhinolaryngologic diseasesHumansPlateletReceptorneoplasmsPharmacologychemistry.chemical_classificationBinding assayInnate immune systemSARS-CoV-2 spike S-proteinLigand binding assayPolyphosphateCOVID-19pathological conditions signs and symptomsdigestive system diseasesCOVID-19 Drug TreatmentAmino acidsurgical procedures operative030104 developmental biologyEnzymechemistryBiochemistry030220 oncology & carcinogenesisSpike Glycoprotein CoronavirusNanoparticlesAlkaline phosphataseAngiotensin-Converting Enzyme 2Protein BindingReceptors Coronavirus

description

Graphical abstract The inorganic physiological polymer, polyphosphate, blocks binding of SARS-CoV-2 spike protein to ACE2 receptor at physiological concentrations. This discovery proposes polyphosphate as a new member of the host's antiviral innate immune defense.

yearjournalcountryeditionlanguage
2020-12-01Biochemical Pharmacology
https://doi.org/10.1016/j.bcp.2020.114215